Navigation Links
Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms
Date:7/27/2009

, disruption in key business activities or any impact on our relationships with third parties as a result of the announcement of the proposed merger; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; the outcome of government investigations; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; global economic conditions; interest and currency exchange rate fluctuations and volatility in the credit and financial markets; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on February 27, 2009. The forward-looking statements in this press release are qualified by these risk factor
'/>"/>
SOURCE Wyeth
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
3. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
4. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
5. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
6. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
7. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
8. Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
9. Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
10. Wyeth Receives FDA Fast Track Designation for its 13-valent Pneumococcal Conjugate Vaccine for Infants and Toddlers
11. Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... N.J. , July 29, 2014 Regado ... company focused on the Phase 3 clinical development of ... controllable antithrombotic drug system, today announced that it will ... Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT to ... highlights. Interested participants and investors may access ...
(Date:7/29/2014)... July 29, 2014  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... for the fiscal third quarter 2014 after the market ... The Company will host a conference call for investors ... Time (10 a.m. Eastern Time). Investors may access the ...
(Date:7/29/2014)... -- New high priced hepatitis C drugs will increase ... $2.9 to $5.8 billion next year, according to a ... by the Pharmaceutical Care Management Association (PCMA). Milliman projects ... much as 8.6 percent in 2015 as a result ... The study finds that the majority of ...
Breaking Medicine Technology:Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
... , SAN CLEMENTE, Calif., Nov. 17 Three ... ages of two through 12 are extremely, very, or ... according to a survey conducted by Opinion Research Corporation ... research of natural remedies including Sinupret® for Kids, a ...
... , DURHAM, N.C., Nov. 17 Oxygen Biotherapeutics, Inc. ... has begun shipping Dermacyte(TM) Oxygen Concentrate Gel to customers ... which are going out today, cover orders received through ... for our company - actually shipping a product to ...
Cached Medicine Technology:Survey Finds Mothers Take Children's Health Into Their Own Hands 2Survey Finds Mothers Take Children's Health Into Their Own Hands 3Survey Finds Mothers Take Children's Health Into Their Own Hands 4Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers 2
(Date:7/30/2014)... 2014 Regents Health Resources, a consulting ... brought health care industry veteran Daryl Demonbreun and former ... lead the company’s ambitious plans to grow into a ... been moving along at a steady pace for nearly ... a notch,” says Bob Maier, founder and chief executive ...
(Date:7/29/2014)... 30, 2014 Recently, iFitDress.com, a well-known wedding ... satin bridal gowns . Aside from this, it has ... up to 68 percent off. All of its old and ... The company’s sales representative says excitedly, “We are pleased to ... new range, there are a lot of amazing items. It ...
(Date:7/29/2014)... Dublin, Ireland (PRWEB) July 30, 2014 ... announced the successful completion of a Phase I trial ... Acid (DGLA). , This study was a randomized, placebo-controlled, ... to assess the safety, pharmacokinetics and effect of food ... confirmed the benign safety profile of DGLA following both ...
(Date:7/29/2014)... Johns Hopkins researchers say they have discovered a chemical ... reactions that, if confirmed in larger studies, could give ... person,s risk of attempting suicide. , The discovery, described ... suggests that changes in a gene involved in the ... a significant role in turning what might otherwise be ...
(Date:7/29/2014)... July 29, 2014 Daily Gossip reveals in ... this program claims that he cured his condition with the ... to share part of his experience. , He claimed ... and naturally in just 4 days. Since his method turned ... sufferers from all around the world. , The Nasal ...
Breaking Medicine News(10 mins):Health News:Sferrella and Demonbreun Join Regents Health Resources 2Health News:Cheap Satin Bridal Gowns Recently Provided By Well-known Supplier iFitDress.com 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2
... HealthDay Reporter , FRIDAY, May 13 (HealthDay News) -- ... to a veterinary clinic near her home in Austin, Texas, when ... like herself," recalled Wong. After running a blood and ... Diabetes is on the rise as America,s cats and dogs grow ...
... in the brains of patients with Alzheimer disease collude, resulting ... cells, according to new findings published online in Neurobiology ... pathological forms of two proteins, amyloid beta and tau, which ... patients plaques and tangles may work in tandem ...
... News) -- Being well-informed about their disease may lead to ... and other emotions about their condition, according to new research. ... were taking medication to manage the disease, and had symptoms ... and abdomen. The women,s coping styles affected their levels ...
... By Dennis Thompson HealthDay Reporter , FRIDAY, May ... the punch line of jokes, prompting chuckles about "mystery meat" ... days, with childhood obesity reaching epidemic proportions in the United ... their kids fit and healthy through proper nutrition. "Five ...
... It,s something we just accept: the fact that the older we ... can leave our ,cars in the same parking lot each morning, ... day, it,s a challenge eight hours later to ,recall whether we ... can ,be introduced to new colleagues at a meeting and will ...
... May 12 (HealthDay News) -- Representatives for veteran TV ... a facility for surgery to remove a meningioma -- ... on the meninges, the brain,s protective outer membrane. ... monitoring this for years, and a neurosurgeon, Mary decided ...
Cached Medicine News:Health News:Fat Cats, Dogs Developing Diabetes, Report Finds 2Health News:Fat Cats, Dogs Developing Diabetes, Report Finds 3Health News:2 defective proteins conspire to impair the nerve cell's 'powerhouse' in Alzheimer's disease 2Health News:2 defective proteins conspire to impair the nerve cell's 'powerhouse' in Alzheimer's disease 3Health News:For Some Women, Knowing About Heart Failure Spurs Worry 2Health News:U.S. Pushes School Cafeterias Toward Healthier Offerings 2Health News:U.S. Pushes School Cafeterias Toward Healthier Offerings 3Health News:As time goes by, it gets tougher to 'just remember this' 2Health News:As time goes by, it gets tougher to 'just remember this' 3Health News:Brain Surgery for Mary Tyler Moore to Remove Benign Tumor 2
Used to remove wrinkles from sections and for reorientating embedded tissue....
... Plus CO-Oximeter Control (Bayer 800 Series) ... in monitoring the performance of blood ... (Bayer 270 and 800 series) instrumentation. ... on Bayer 800 Rapidlab Series instruments ...
Prevents formation of microscopic ice crystals and sample distortion caused by slow freezing of hyperosmolar tissue samples in conventional cyrostats....
Liquichek Blood Gas Plus CO-Oximeter Control (IL Synthesis Series) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximetry anal...
Medicine Products: